ADC开发解决方案
抗体偶联药物( antibody-drug conjugate，ADC) 是将单克隆抗体药物的高特异性和小分子细胞毒药物的高活性相结合，用以提高肿瘤药物的靶向性、减少毒副作用。ADC抗体分子的筛选是ADC临床转化前的重要基础，是保证ADC临床有效性和安全性的关键。
缔码生物针对每个ADC热门靶点，已经开发出几十种预先开发好的先导分子，同时建立了一整套ADC临床前药效学评价平台。
ADC 开发流程
5000+ 现货先导抗体分子
覆盖400+ 药靶
人/猴交叉反应评估
亲和力排序
体外肿瘤细胞抑制试验
体内肿瘤抑制试验
毒素偶联
内吞测试
案例展示
ADC Cell Killing Assay with MMAE conjugated GPRC5D Antibodies (Ab1 and Ab2)
Specific Cell Killing by Anti-GPRC5D Antibodies Conjugated with MMAE
In this experiment, three cell types were tested: K562 (negative control, left), K562-GPRC5D (positive cells, center), and H929 (GPRC5D-expressing natural cell line, right). The black and red curves represent MMAE-conjugated anti-GPRC5D antibodies (Ab1/2), showing specific killing of GPRC5D-positive cells. The blue curve represents MMAE-conjugated anti-GPRC5D positive control antibodies, and the green curve represents MMAE-conjugated IgG negative control. The data demonstrates the specific cytotoxicity of anti-GPRC5D antibodies against GPRC5D-positive cells following MMAE conjugation.
Cyno and mouse cross-reactivity tests
Cross-Reactivity Analysis of GPRC5D Candidate Antibodies with Cyno and Mouse GPRC5D Positive Cells Using FACS
In this study, we assessed four distinct cell types: 293T-hu GPRC5D, 293-cyno GPRC5D, 293-mouse GPRC5D, and 293T-negative control. The negative control, 293-PTT5 cells, lacked overexpressed GPRC5D proteins, while the other cells contained overexpressed GPRC5D proteins from human, cyno, and mouse species. We employed candidate antibodies, including G01~G09 (humanized antibodies developed by DIMA Bio) and G00 (a humanized antibody molecule developed by Eureka Therapeutics), to interact with these four cell types using FACS. Our data clearly reveals that G00, G05, G07, and G09 antibodies exhibit cross-reactivity with Cynomolgus Monkey GPRC5D, while the G00 antibody displays cross-reactivity with Mouse GPRC5D.
DiTag TM IgG Labeling Reagent for Antibody Internailzaiton Assay
Antibody Internalization Assay with DiTag TM Reagents
Specific Internalization of GPRC5D ADC BMK-AME100001 Conjugate in GPRC5D-Positive Cells (K562-GPRC5D Stable Expression Cell Line, Right), with No Detection in K562 Cells Lacking GPRC5D Overexpression (Left).
Specific Internalization of GPRC5D ADC BMK-AME100002 Conjugate in GPRC5D-Positive Cells (K562-GPRC5D Stable Expression Cell Line, Right), with No Detection in K562 Cells Lacking GPRC5D Overexpression (Left).
Stability Testing for DiTag TM Reagents
Stability test of AME100001: Three storage methods are tested: lyophilization and reconstitution (black), liquid with 50% glycerol at -20℃ (red), liquid at 4℃ (blue). All three methods exhibit excellent stability.
Reagents for ADC payload detection
Figure1. Elisa plates were pre-coated with IgG-MMAE (0.2μg/per well). Serial diluted anti-MMAE monoclonal antibody (DME101004) solutions were added, washed, and incubated with secondary antibody before Elisa reading. From above data, the EC50 for anti-MMAE monoclonal antibody binding with IgG-MMAE is 1.356ng/ml.
ADC开发工具
广泛的先导抗体分子：
拥有5000+现货先导抗体分子，
覆盖400+ 药靶（包含ADC热门靶标）
人/猴稳转细胞系：
我们专注于稳定细胞系构建，使跨物种转化研究更加高效。
丰富的B细胞克隆：
我们的单B细胞技术可生成多种B细胞克隆，
可为抗体筛选提供广泛的候选选择.
DiTag™抗体标记试剂：
该试剂旨在评估ADC候选分子的内吞能力，是高效筛选候选分子的宝贵工具。
DiLibrary™ 平台:
我们创新的基于哺乳动物细胞展示的抗体工程改造平台可以更高效的实现抗体人源化。这是ADC药物开发的关键一步。
Anti-Payload抗体:
缔码研发的Anti-Payload抗体在众多药物测试中展现了显著功效，在推进ADC开发方面拥有巨大潜力。目前已完成anti-MMAE抗体、anti-Dxd抗体和anti-SN38抗体开发，更多Anti-Payload抗体，敬请期待。
缔码生物致力于推动ADC研究，并为研究人员提供所需的工具和技术服务，以便于更好的定义精准医疗。我们邀请您加入我们的变革之旅，共创癌症治疗的未来。
ADC 热门产品
| 货号 | 特色产品 |
|---|---|
| AME100001 | DiTagTM pH sensitive IgG labeling reagent |
| AME100002 | DiTagTM pH sensitive IgG labeling reagent plus |
| AME100003 | DiTagTM MMAE IgG labeling reagent |